Implementing Expert Treatment Strategies in the Management of Inflammatory Bowel Disease

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2020 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from November 1, 2020 to March 1, 2022

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Takeda Pharmaceuticals USA

Description:
Inflammatory bowel disease (IBD) is a chronic, frequently progressive condition that affects approximately 1.6 million people in the United States. This lifelong, systemic autoimmune illness often strikes patients at a young age and must be managed across a lifetime. The diagnosis of IBD is most commonly based on imaging to assess the portions of the small bowel that are inaccessible to optical endoscopic visualization, which may also include a combination of endoscopy and histopathology. Imaging plays a critical role in the initial diagnosis and ongoing evaluation of IBD patients. The treatment goal for IBD is to reduce the inflammation, in hopes of achieving reduced symptoms and possibly remission. Immediate goals are to control the symptoms, induction of remission, and to help improve a patient’s quality of life, while long-term goals include maintenance of a corticosteroid-free clinical remission, mucosal healing, endoscopic remission, prevention or cure of complications, restoration, and maintenance of proper nutrition. The first step for IBD treatment is aminosalicylates, which are useful for treating flares of IBD and for maintaining remission. There is also the use of antibiotics to treat bacterial infections that may result from abscesses or fistulas. Corticosteroids can be used, as they are rapid-acting anti-inflammatory agents, are indicated for acute flares of disease only and have no role in the maintenance of remission. Immunomodulators have a slower onset of action and work to reduce patients’ overactive immune system but unlike corticosteroids, they can be used as a long-term treatment. And the fifth way to treat IBD is with biologics, which are proteins that stop certain molecules in the body from causing inflammation in the GI tract. These are usually prescribed to those living with moderate to severe cases of IBD who have not responded to other types of treatment.

Advances in IBD treatment have improved outcomes for many patients but personalizing therapy and predicting response to therapy continues to be a big challenge. This has led to underutilization of effective regimens, undertreatment, and suboptimal outcomes. Addressing new and emerging clinical decision support tools can help providers bridge this gap by predicting individualized disease complication risk and appropriate responses to therapy. Currently, there are several approved biologics and small molecules available through the FDA and other regulatory organizations around the world. One of these treatments is the tumor necrosis factor (TNF) inhibitors. Another treatment pathway is blocking interleukin (IL)-12 and -23 through the use of ustekinumab. A completely different mechanism is blocking the adhesion molecules to the integrin inhibitors. Then, more recently there have been advances in the first oral agents which consist of the Janus kinase (JAK) inhibitors. New updates in these treatments, as well as the presence of biologic therapies, has changed goals and expectations of inflammatory bowel disease management and gives patients a better chance of achieving remission.

Upon completion of this activity, participants will be able to:

  • Analyze the safety and efficacy of current and emerging treatments to inform treat-to-target strategies in the management of inflammatory bowel disease (IBD)

  • Explore different indications of proper diagnostic testing to determine optimal customized treatment strategies

  • Incorporate the use of biologics, combination therapies, and emerging agents with novel mechanisms of action in the current IBD treatment paradigm

  • Discuss challenges in IBD management and how to overcome issues concerning adherence and adverse effects

  • Evaluate managed care strategies and guidelines to help account for evolving management strategies in IBD

     

Faculty: Miguel Regueiro, MD
Chair, Department of Gastroenterology, Hepatology & Nutrition
Professor, Department of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

Disclosure:

Dr. Regueiro serves on an advisory board and as a consultant for AbbVie, Janssen, UCB, Takeda, Pfizer, Miraca Labs, Amgen, Celgene, Seres, Allergan, Genentech, Gilead, Salix, and Prometheus. He has received grants/research support from AbbVie, Janssen, Pfizer and Takeda. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Takeda Pharmaceuticals USA

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue